Niagen Bioscience, Inc.

Healthcare · Biotechnology · —

3.00$ +0.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Niagen Bioscience, Inc. (NAGE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 107 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NAGE
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	19	20	21	33	42	63	57	52	47	42	42	45	43	40	36	42	37	38	69	66	60	58	53	47	46	54	54	53	53	55	54	54	57	68	81	92	98	106	114	107
Current Assets	15	16	16	27	36	57	53	46	41	37	35	38	36	34	29	36	31	32	63	58	53	49	45	39	38	47	47	46	47	50	49	49	52	64	76	87	94	97	105	98
Cash	2.3	1.6	1.2	14	24	45	41	33	28	22	19	20	19	19	13	19	15	16	44	39	33	28	21	17	13	20	23	26	27	27	27	28	32	45	55	60	64	65	67	67
Cash & Short-Term Investments	2.3	1.6	1.2	14	24	45	41	33	28	22	19	20	19	19	13	19	15	16	44	39	33	28	21	17	13	20	23	26	27	27	27	28	32	45	55	60	64	65	67	67
Receivables	6.5	5.9	5.0	4.6	4.9	5.3	4.8	5.2	4.8	4.4	5.4	5.8	6.0	2.2	3.6	4.0	3.2	2.7	4.6	6.0	5.3	5.2	6.3	4.2	4.7	8.5	9.2	6.1	5.6	5.2	6.6	7.8	7.1	7.8	7.1	9.7	8.5	9.7	13	8.6
Inventory	6.3	7.9	8.9	7.8	6.6	5.8	5.1	6.5	7.1	8.2	8.7	11	9.8	12	11	12	11	12	13	12	13	14	15	16	16	15	12	12	13	15	12	12	11	9.2	11	14	19	20	24	21
Intangible Assets	0.5	0.5	1.8	1.8	1.7	1.7	1.6	1.5	1.5	1.5	1.5	1.4	1.4	1.3	1.2	1.2	1.1	1.1	1.0	1.0	0.9	0.9	0.8	0.8	0.7	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3	0.2	5.7	5.5	5.3
Total Liabilities	6.9	9.8	12	7.2	8.1	8.9	11	12	14	15	21	29	16	20	19	20	18	22	25	24	25	26	27	26	25	25	26	26	26	27	25	23	22	22	26	27	27	30	32	24
Current Liabilities	6.4	8.9	11	6.3	7.2	8.1	10	11	13	14	16	24	11	15	14	16	13	16	20	16	18	18	19	18	17	18	18	19	19	21	19	18	18	18	21	22	23	20	23	15
Short-Term Debt	0.2	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.8	11	0.9	0.9	0.8	0.8	0.7	0.6	0.5	0.5	0.5	0.5	0.6	0.7	0.7	0.7	0.7	0.8	0.9	0.7	0.9	1.0	1.0	1.0	0.9	1.0	1.0	1.0	1.0	0.9
Accounts Payable	4.1	6.0	7.9	3.1	4.3	3.7	5.9	6.8	8.9	9.5	9.8	9.3	6.2	9.6	8.2	9.8	6.9	9.4	12	10.0	11	10	9.8	10	9.1	9.7	9.0	10	9.2	10	7.9	8.1	6.9	8.5	11	14	13	11	13	9.4
Shareholders' Equity	12	10.0	9.4	26	34	54	47	41	33	27	21	15	27	20	17	22	19	16	44	42	35	32	26	21	21	29	28	27	27	28	29	31	34	46	55	64	71	77	82	83
Retained Earnings	-43	-45	-47	-50	-48	-57	-65	-73	-82	-90	-98	-106	-113	-122	-128	-132	-136	-142	-149	-155	-164	-169	-177	-183	-184	-185	-187	-190	-191	-190	-191	-191	-189	-182	-177	-173	-169	-165	-158	-157
Shares Outstanding	38	38	38	42	48	51	55	55	55	55	55	56	58	60	60	61	62	62	64	68	68	68	68	68	68	74	75	75	75	75	75	76	78	82	83	86	87	84	85	83

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings